Journal article · 2025 · Open access

Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial

Evangelos J. Giamarellos‐Bourboulis, Antigone Kotsaki, Ioanna Kotsamidi, Aikaterini Efthymiou, Vasiliki Koutsoukou, Johannes Ehler, Alexandra Paridou, Frantzeska G. Frantzeskaki, Marcella C.A. Müller, Peter Pickkers, Sylvain Meylan, Ioannis Nikolopoulos and 278 more

JAMA, 335(9), 775 · Published 8 December 2025 · DOI 10.1001/jama.2025.24175

Open full textView at the publisherCite this paper

In brief

“Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial” is a 2025 journal article by Evangelos J. Giamarellos‐Bourboulis and 289 co-authors, published in JAMA. OpenAlex counts 153 citations as of 16 November 2026. It is open access under a CC BY licence: the full text is free to read at Pure Amsterdam UMC.

Citations
153
Most cited in
2026 (152)
Field-weighted impact
78.59
References
22
Authors
290

Abstract

Importance: Sepsis is heterogeneous, and the optimal strategy for tailoring immunotherapy is uncertain. Objective: To investigate whether precision immunotherapy guided by the presence of macrophage activation-like syndrome or sepsis-induced immunoparalysis improves organ dysfunction by day 9. Design, Setting, and Participants: A randomized, double-blind, double-dummy, placebo-controlled clinical trial conducted in 6 countries. Patients with sepsis, defined by Sepsis-3, were included if they had community-acquired or hospital-acquired pneumonia or ventilator-associated pneumonia or bacteremia and sepsis and had displayed either macrophage activation-like syndrome (blood ferritin >4420 ng/mL) or sepsis-induced immunoparalysis (blood ferritin ≤4420 ng/mL and <5000 human leukocyte antigen DR receptors on CD45/CD14 monocytes). The first patient was enrolled August 5, 2021, and the last follow-up, April 29, 2024. Interventions: Eligible patients were randomized to receive standard care and precision immunotherapy or standard care and placebo. Those in the precision immunotherapy group with macrophage activation-like syndrome received anakinra intravenously (IV) and placebo subcutaneously, and those with sepsis-induced immunoparalysis received subcutaneous recombinant human interferon gamma and IV placebo. Those in the placebo group received both IV and subcutaneous placebo. Treatment was administered for up to 15 days. Main Outcomes and Measures: The primary end point was a decrease of at least 1.4 points in the mean Sequential Organ Failure Assessment (SOFA) score from baseline by day 9. The SOFA score evaluates 6 organ systems, ranging from 0, no dysfunction, to 4, failure, and the total score ranges from 0, normal, to 24, most severe form of multiorgan failure. Key secondary outcomes included 28-day mortality. Results: Of 672 patients assessed for eligibility, 281 were randomized and 276 were included in the primary analysis population (mean [SD] age, 70 [13] years; 93 females [33.7%]; median baseline SOFA score, 9 [IQR, 7-11]). The SOFA decrease end point was attained by 46 of 131 patients (35.1%) in the precision immunotherapy group and by 26 of 145 patients (17.9%) in the placebo group (difference, 17.2% [95% CI, 6.8% to 27.2%]; P = .002). Mortality at 28 days was not statistically significantly different between groups. A total of 1069 serious treatment-emergent adverse events (88.8%) were reported; increased incidence of anemia was noted in the anakinra group; and hemorrhage in the recombinant human interferon gamma group. Conclusions and Relevance: Among patients with sepsis, precision immunotherapy targeting macrophage activation-like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared with placebo. Trial Registration: ClinicalTrials.gov Identifier: NCT04990232.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Giamarellos‐Bourboulis, E. J., Kotsaki, A., Kotsamidi, I., Efthymiou, A., Koutsoukou, V., Ehler, J., Paridou, A., Frantzeskaki, F. G., Müller, M. C., Pickkers, P., Meylan, S., Nikolopoulos, I., Lupșe, M. S., Gavala, A., Vlachogianni, G., Solomonidi, N., Alevizou, A., Kondili, Ε., Antoniadou, E., . . . Tanzarella, E. S. (2025). Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. JAMA, 335(9), 775. https://doi.org/10.1001/jama.2025.24175

MLA 9

Giamarellos‐Bourboulis, Evangelos J., et al. “Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.” JAMA, vol. 335, no. 9, 2025, p. 775. https://doi.org/10.1001/jama.2025.24175.

Chicago

Giamarellos‐Bourboulis, Evangelos J., Antigone Kotsaki, Ioanna Kotsamidi, Aikaterini Efthymiou, Vasiliki Koutsoukou, Johannes Ehler, Alexandra Paridou, et al. 2025. “Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.” JAMA 335 (9): 775. https://doi.org/10.1001/jama.2025.24175.

Harvard

Giamarellos‐Bourboulis, E. J. et al. (2025) ‘Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial’, JAMA, 335(9), p. 775. doi:10.1001/jama.2025.24175.

IEEE

E. J. Giamarellos‐Bourboulis et al., “Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial,” JAMA, vol. 335, no. 9, p. 775, 2025, doi: 10.1001/jama.2025.24175.

BibTeX

@article{giamarellosbourboulis2025precision,
  title     = {{Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial}},
  author    = {Giamarellos‐Bourboulis, Evangelos J. and Kotsaki, Antigone and Kotsamidi, Ioanna and Efthymiou, Aikaterini and Koutsoukou, Vasiliki and Ehler, Johannes and Paridou, Alexandra and Frantzeskaki, Frantzeska G. and Müller, Marcella C.A. and Pickkers, Peter and Meylan, Sylvain and Nikolopoulos, Ioannis and Lupșe, Mihaela Sorina and Gavala, Alexandra and Vlachogianni, Glykeria and Solomonidi, Nicky and Alevizou, Antonia and Kondili, Εumorfia and Antoniadou, Eleni and Nakou, Maria and Μάρκου, Νικόλαος and Hatziagelaki, Erifili E. and Prekates, Athanassios and Komnos, Apostolos and Bakkerus, Lieke and Slim, Marleen A. and Dalekos, George Ν. and Karapanagiotou, Areti and Ktena, Sofia Ira and DE PASCALE, Gennaro and others},
  journal   = {JAMA},
  year      = {2025},
  volume    = {335},
  number    = {9},
  pages     = {775},
  doi       = {10.1001/jama.2025.24175},
  url       = {https://doi.org/10.1001/jama.2025.24175}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment

  • sepsis
  • precision immunotherapy
  • anakinra
  • recombinant interferon-gamma
  • SOFA score
  • organ dysfunction
  • 28-day mortality
  • ferritin

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Giamarellos‐Bourboulis, E. J., Kotsaki, A., Kotsamidi, I., Efthymiou, A., Koutsoukou, V., Ehler, J., Paridou, A., Frantzeskaki, F. G., Müller, M. C., Pickkers, P., Meylan, S., Nikolopoulos, I., Lupșe, M. S., Gavala, A., Vlachogianni, G., Solomonidi, N., Alevizou, A., Kondili, Ε., Antoniadou, E., . . . Tanzarella, E. S. (2025). Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. JAMA, 335(9), 775. https://doi.org/10.1001/jama.2025.24175

How many times has this paper been cited?

153 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Pure Amsterdam UMC: sign in and open the full text from this page.

Who wrote this paper?

Evangelos J. Giamarellos‐Bourboulis, Antigone Kotsaki, Ioanna Kotsamidi, Aikaterini Efthymiou, Vasiliki Koutsoukou, Johannes Ehler, Alexandra Paridou, Frantzeska G. Frantzeskaki, Marcella C.A. Müller, Peter Pickkers, Sylvain Meylan, Ioannis Nikolopoulos and 278 more.

What is the DOI of this paper?

10.1001/jama.2025.24175, permanently at https://doi.org/10.1001/jama.2025.24175. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.